Individuals taking extended-release injection naltrexone for opioid use disorder may be less likely to drop out of treatment after a single use of opioids compared with patients receiving placebo.
Prenatal opioid exposure may be associated with poorer cognitive and motor development in children from age 6 months to adolescence.
The US Food and Drug Administration has provided fast-track approval for the nonclinician use of Evzio, an easy-to-use autoinjectable device with a single dose of naloxone for the reversal of opioid overdose.
There may be a bidirectional association between migraine and some comorbid psychiatric disorders.
The prevalence of cluster headache may be higher in individuals with a substance use disorder than in the general population.
Opioid-related deaths, particularly those associated with synthetic opioids, increased in the eastern United States between 1999 and 2016, leading to lower life expectancies.
Current policy interventions aiming to curb opioid-related deaths are unlikely to be effective in the coming years.
Adolescents with atypical anorexia nervosa have higher bone mass density on average than adolescents with anorexia nervosa, but still experience significant deficits in fat mass index.
A panel of experts addressed several challenges associated with the implementation of the 2016 Centers for Disease Control and Prevention Guideline for Prescribing Opioids for Chronic Pain.
Compared with patients who have onset type 2 diabetes at a usual age, adults with young-onset T2D are hospitalized significantly more often in their lifetimes.
